PortalPublikationenTrends in outcome of transplantation in patients with second...

Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT

Standard

Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. / Nagler, Arnon; Ngoya, Maud; Galimard, Jacques-Emmanuel; Labopin, Myriam; Kröger, Nicolaus; Socié, Gerard; Gedde-Dahl, Tobias; Potter, Victoria; Schroeder, Thomas; Platzbecker, Uwe; Ganser, Arnold; Blaise, Didier; Salmenniemi, Urpu; Maertens, Johan; Craddock, Charles; Labussière-Wallet, Hélène; Yakoub-Agha, Ibrahim; Savani, Bipin; Mohty, Mohamad.

in: BONE MARROW TRANSPL, Jahrgang 57, Nr. 12, 12.2022, S. 1788-1796.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Nagler, A, Ngoya, M, Galimard, J-E, Labopin, M, Kröger, N, Socié, G, Gedde-Dahl, T, Potter, V, Schroeder, T, Platzbecker, U, Ganser, A, Blaise, D, Salmenniemi, U, Maertens, J, Craddock, C, Labussière-Wallet, H, Yakoub-Agha, I, Savani, B & Mohty, M 2022, 'Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT', BONE MARROW TRANSPL, Jg. 57, Nr. 12, S. 1788-1796. https://doi.org/10.1038/s41409-022-01825-0

APA

Nagler, A., Ngoya, M., Galimard, J-E., Labopin, M., Kröger, N., Socié, G., Gedde-Dahl, T., Potter, V., Schroeder, T., Platzbecker, U., Ganser, A., Blaise, D., Salmenniemi, U., Maertens, J., Craddock, C., Labussière-Wallet, H., Yakoub-Agha, I., Savani, B., & Mohty, M. (2022). Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. BONE MARROW TRANSPL, 57(12), 1788-1796. https://doi.org/10.1038/s41409-022-01825-0

Vancouver

Nagler A, Ngoya M, Galimard J-E, Labopin M, Kröger N, Socié G et al. Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. BONE MARROW TRANSPL. 2022 Dez;57(12):1788-1796. https://doi.org/10.1038/s41409-022-01825-0

Bibtex

@article{955569f052cb493c9e948de2e608d286,
title = "Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT",
abstract = "Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000-2010 and 2887 in 2011-2020. Median age was 54 (range, 18-74) and 59 (range, 18-78) years, respectively (p < 0.0001). Donors were MSD in 65% vs. 37%, 10/10 UD in 27% vs. 50%, and 9/10 UD in 8% vs. 13%, respectively (p < 0.0001). Conditioning was myeloablative in 46% and 38%, respectively. Two-year non-relapse mortality (NRM) was lower in patients transplanted in 2011-2020 vs. those transplanted in 2000-2010, 18% vs. 21% (hazard ratio (HR) = 0.82, 95% CI: 0.68-0.9; p = 0.04) and modified GVHD-free, relapse-free survival (GRFS) (HR = 0.9, 95% CI: 0.81-0.99; p = 0.04) was better in patients transplanted in the 2011-2020 vs. those transplanted in 2000-2010. Two-year relapse incidence (RI) was similar between the 2 groups with 32% vs. 31%, (HR = 1.05, 95% CI: 0.9-1.22; p = 0.55). Likewise, leukemia-free survival (LFS) (HR = 0.95, 95% CI: 0.84-1.07; p = 0.38) and overall survival (OS) (HR = 0.93, 95% CI: 0.82-1.05; p = 0.26) were not significantly different between the two periods. In conclusion, Incidence of NRM has been significantly reduced and GRFS significantly increased in HSCT for sAML in the last 2 decades.",
keywords = "Humans, Middle Aged, Hematopoietic Stem Cell Transplantation/methods, Leukemia, Myeloid, Acute, Transplantation Conditioning/methods, Neoplasms, Second Primary/etiology, Remission Induction, Recurrence, Retrospective Studies, Graft vs Host Disease/etiology",
author = "Arnon Nagler and Maud Ngoya and Jacques-Emmanuel Galimard and Myriam Labopin and Nicolaus Kr{\"o}ger and Gerard Soci{\'e} and Tobias Gedde-Dahl and Victoria Potter and Thomas Schroeder and Uwe Platzbecker and Arnold Ganser and Didier Blaise and Urpu Salmenniemi and Johan Maertens and Charles Craddock and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and Ibrahim Yakoub-Agha and Bipin Savani and Mohamad Mohty",
note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
month = dec,
doi = "10.1038/s41409-022-01825-0",
language = "English",
volume = "57",
pages = "1788--1796",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT

AU - Nagler, Arnon

AU - Ngoya, Maud

AU - Galimard, Jacques-Emmanuel

AU - Labopin, Myriam

AU - Kröger, Nicolaus

AU - Socié, Gerard

AU - Gedde-Dahl, Tobias

AU - Potter, Victoria

AU - Schroeder, Thomas

AU - Platzbecker, Uwe

AU - Ganser, Arnold

AU - Blaise, Didier

AU - Salmenniemi, Urpu

AU - Maertens, Johan

AU - Craddock, Charles

AU - Labussière-Wallet, Hélène

AU - Yakoub-Agha, Ibrahim

AU - Savani, Bipin

AU - Mohty, Mohamad

N1 - © 2022. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022/12

Y1 - 2022/12

N2 - Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000-2010 and 2887 in 2011-2020. Median age was 54 (range, 18-74) and 59 (range, 18-78) years, respectively (p < 0.0001). Donors were MSD in 65% vs. 37%, 10/10 UD in 27% vs. 50%, and 9/10 UD in 8% vs. 13%, respectively (p < 0.0001). Conditioning was myeloablative in 46% and 38%, respectively. Two-year non-relapse mortality (NRM) was lower in patients transplanted in 2011-2020 vs. those transplanted in 2000-2010, 18% vs. 21% (hazard ratio (HR) = 0.82, 95% CI: 0.68-0.9; p = 0.04) and modified GVHD-free, relapse-free survival (GRFS) (HR = 0.9, 95% CI: 0.81-0.99; p = 0.04) was better in patients transplanted in the 2011-2020 vs. those transplanted in 2000-2010. Two-year relapse incidence (RI) was similar between the 2 groups with 32% vs. 31%, (HR = 1.05, 95% CI: 0.9-1.22; p = 0.55). Likewise, leukemia-free survival (LFS) (HR = 0.95, 95% CI: 0.84-1.07; p = 0.38) and overall survival (OS) (HR = 0.93, 95% CI: 0.82-1.05; p = 0.26) were not significantly different between the two periods. In conclusion, Incidence of NRM has been significantly reduced and GRFS significantly increased in HSCT for sAML in the last 2 decades.

AB - Trends in outcome of transplantation (HSCT) in secondary acute myeloid leukemia (sAML) are limited. We evaluated results of HSCT in 4224 patients with sAML in complete remission; 1337 were transplanted in 2000-2010 and 2887 in 2011-2020. Median age was 54 (range, 18-74) and 59 (range, 18-78) years, respectively (p < 0.0001). Donors were MSD in 65% vs. 37%, 10/10 UD in 27% vs. 50%, and 9/10 UD in 8% vs. 13%, respectively (p < 0.0001). Conditioning was myeloablative in 46% and 38%, respectively. Two-year non-relapse mortality (NRM) was lower in patients transplanted in 2011-2020 vs. those transplanted in 2000-2010, 18% vs. 21% (hazard ratio (HR) = 0.82, 95% CI: 0.68-0.9; p = 0.04) and modified GVHD-free, relapse-free survival (GRFS) (HR = 0.9, 95% CI: 0.81-0.99; p = 0.04) was better in patients transplanted in the 2011-2020 vs. those transplanted in 2000-2010. Two-year relapse incidence (RI) was similar between the 2 groups with 32% vs. 31%, (HR = 1.05, 95% CI: 0.9-1.22; p = 0.55). Likewise, leukemia-free survival (LFS) (HR = 0.95, 95% CI: 0.84-1.07; p = 0.38) and overall survival (OS) (HR = 0.93, 95% CI: 0.82-1.05; p = 0.26) were not significantly different between the two periods. In conclusion, Incidence of NRM has been significantly reduced and GRFS significantly increased in HSCT for sAML in the last 2 decades.

KW - Humans

KW - Middle Aged

KW - Hematopoietic Stem Cell Transplantation/methods

KW - Leukemia, Myeloid, Acute

KW - Transplantation Conditioning/methods

KW - Neoplasms, Second Primary/etiology

KW - Remission Induction

KW - Recurrence

KW - Retrospective Studies

KW - Graft vs Host Disease/etiology

U2 - 10.1038/s41409-022-01825-0

DO - 10.1038/s41409-022-01825-0

M3 - SCORING: Journal article

C2 - 36114249

VL - 57

SP - 1788

EP - 1796

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 12

ER -